Japanese company profile · 4880
CellSource Co.,Ltd.
In its FY2024 public filing, CellSource Co.,Ltd. reports Regenerative Medicine-related Business. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: セルソース株式会社
English company name recorded in Japan's EDINET filer data. English company name source
Reported company-wide figures
What does this company do?
What does this company do?
CellSource Co.,Ltd.'s largest reported business by revenue in FY2024 was Regenerative Medicine-related Business.
The business with the highest reported segment profit in FY2024 was Regenerative Medicine-related Business.
FY2024 · fiscal year ended October 2025 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Sales | Revenue share | Operating profit |
|---|---|---|---|
| Regenerative Medicine-related Business | ¥3.71B ↗ | 100.0% | ¥166.71M ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2024 · fiscal year ended October 2025. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Regenerative Medicine-related Business
- 再生医療関連事業
- Sales
- 売上高
- Operating profit
- 営業利益
Original Japanese label
- Regenerative Medicine-related Business
- 再生医療関連事業
- Sales
- 売上高
- Operating profit
- 営業利益
What is growing?
What is growing?
No comparable reported revenue growth is available.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2024 · fiscal year ended October 2025
The source document may be in Japanese.
Filing ID: S100XHWF
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.